Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New study suggests role for clazosentan in the prevention of cerebral vasospasm after aneurysmal SAH

04.07.2005


Actelion Ltd (SWX: ATLN) announced today that a study published in the July edition of the Journal of Neurosurgery suggests that clazosentan can reduce the number and severity of cases of vasospasm following aneurysmal subarachnoid haemorrhage (SAH).1

Vasospasm occurs 5-14 days following SAH and leads to strokes and neurological deficits that cause significant disability to patients and is a major cause of death. As many as 70% of people who have aneurysmal SAH may have arterial narrowing and even with the most advanced surgical and endovascular advances in securing the aneurysm, the outcomes remain poor with up to 30% developing neurological deficits or dying2.

This Phase IIa study with 34 patients demonstrated that patients given the i.v. endothelin receptor antagonist clazosentan continuously for up to 14 days suffered from significantly fewer and less severe cases of vasospasm compared to placebo. Only 40% of patients treated with clazosentan developed cerebral vasospasm, as diagnosed on angiography, compared to 88% of patients treated with placebo (p=0.008).1



Furthermore, there were fewer patients with new cerebral infarcts in the clazosentan group – 15% versus 44% in the placebo group. Overall the nature and severity of adverse events were comparable between the two treatment groups. Infusions of clazosentan were generally well tolerated, with no clinically relevant effects on blood pressure or other vital signs.1

Dr Peter Vajkoczy, Neurosurgeon at the Department of Neurosurgery, University Hospital, Mannheim, and the main author of the study comments: "While our understanding of cerebral vasospasm has continued to improve, a solution to this challenge is yet to be found. However, these results are certainly promising and it is important that these findings are assessed and confirmed in a larger population to identify how clazosentan may have an impact in clinical practice."

The July edition of JNS also carries an editorial focusing on the clazosentan study. Dr Neal Kassell, Professor and Co-chairman of the Department of Neurological Surgery at the University of Virginia comments: "It is encouraging to finally, after nearly one-half century of futile investigations, be able to introduce into clinical trials an agent that, based on experimental studies, has a real potential for preventing vasospasm and, based on preliminary clinical studies, appears to be without significant side effects (including hypotension), as well as exhibiting a suggestion of efficacy."

Following detailed discussions with regulatory authorities worldwide, the findings of this study have already led to the initiation of a comprehensive Phase IIb/III development programme for clazosentan. A multi-centre, international, double-blind, randomized, placebo-controlled, parallel group, dose-finding study CONSCIOUS-1 (Clazosentan to Overcome Neurological iSChemia and Infarct OccUrring after Subarachnoid hemorrhage) will analyse the efficacy of 3 dose levels of clazosentan in preventing the occurrence of cerebral vasospasm following SAH, assessed by angiography. As a secondary endpoint, the study will also assess the ability of clazosentan to reduce the occurrence of early morbidity/mortality as well as overall safety and tolerability of the drug.

CONSCIOUS-1 is expected to recruit 400 patients in approximately 70 centers in 13 countries worldwide. Study results are expected in the first half of 2006. These results will determine the need, size and duration of a Phase III study.

Two pre-clinical studies suggest impact of clazosentan on endothelin receptors A and B This study follows the publication in the June edition of the JNS of two pre-clinical studies which characterised the inhibitory effect of clazosentan on endothelin A (ETA) receptor mediated contraction and endothelin B (ETB) receptor mediated relaxation.3,4

References:

1. Vajkoczy P, Meyer B, Weidauer S et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled, multicenter, Phase IIa study. Journal of Neurosurgery July 2005. 103, 9-17.
2. Harrod, CG, Bendok BR, Batjer HH et al. Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review. Neurosurgery. April 2005. 56, 633-652.
3. Vatter H, Zimmermann M, Tesanovic V et al. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: Inhibitory effect on endothelinA receptor–mediated contraction. Journal of Neurosurgery. June 2005. 102, 1101-1107.
4. Vatter H, Zimmermann M, Tesanovic V et al Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: Effect on endothelinB receptor–mediated relaxation. Journal of Neurosurgery. June 2005. 102, 1108-1114.
5. Wolf PA. Epidemiology of intracerebral haemorrhage. In: Carlos SK, Louis RC, editors. Intracerebral haemorrhage. United States of America: Butterworth Heinemann, 1996: 23.

Alexa Forbes | EurekAlert!
Further information:
http://www.actelion.com
http://www.packerforbes.com

More articles from Studies and Analyses:

nachricht Real-time feedback helps save energy and water
08.02.2017 | Otto-Friedrich-Universität Bamberg

nachricht The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>